The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change-4.3% to $254.00
Predicted High$264.20in 2 weeks
Predicted Low$254.00at 6 months
Max Drawdown (predicted)-4.3%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Jul 30, 2026 1:12 am
Neutral
JNJ trends range-bound to
$254.00
(-4.3% from $265.53)
by Jan 2027.
decay
ThesisJNJ trades well above composite fair value ($171-179) but its defensive profile, quality score, and earnings consistency support price stickiness. Expect mild drift lower as valuation gravity slowly asserts itself in a stress regime, though the low beta cushions downside. No near-term earnings catalyst to force a repricing.
Invalidated ifA break above $280 on positive pharma catalyst, or a break below $245 signaling valuation compression has begun in earnest.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $265.53 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Jul 30, 2026
—
$265.53at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Aug 13, 2026
$252.79–$278.27typical range · internal point $264.20
—
±4.8%
7/10
Low-beta defensive holds in stress tape near-term
What actually happened:
closed $260.86
on Aug 12, 2026 = -1.8% vs the call
(predicted -0.5%)
· direction HIT
(called flat, was flat)
· off by 1.3 pp
· accuracy 10/10
· typical range ±4.8%:
inside the band
· S&P +4.2%
over the same window — beat it
1 month
Aug 30, 2026
$247.07–$283.99typical range · internal point $263.00
—
±7.0%
6/10
Mild drift as talc headline weighs modestly
2 months
Sep 30, 2026
$261.50
—
-1.5%
5/10
Q3 print approaches with no calendar catalyst yet
3 months
Oct 30, 2026
$259.00
—
-2.5%
5/10
Valuation gravity begins nudging toward fair value
Drift toward deterministic baseline as sentiment stale
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$254.51
(-4.1%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.